Overview

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Glycopyrrolate